MAPT and Alzheimer disease: Specifically, participants with more significant MCI symptoms at study entry had an increased prevalence of the APOE-ε4 allele along with greater CSF biomarker evidence of AD pathology (Aβ42 and p-tau) and neurodegeneration (t-tau and neurogranin).